Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Carriers: This group comprises the primary study population and consists of individuals who carry the HD gene expansion mutation.
* Controls: This group comprises the comparator study population and consists of individuals who do not carry the HD expansion mutation.
These two major categories can be further subdivided into six different subgroups of eligible individuals:
* Manifest/Motor-manifest HD: Carriers with clinical features that are regarded in the opinion of the investigator as diagnostic of HD.
* Pre-Manifest/-Motor-manifest HD: Carriers without clinical features regarded as diagnostic of HD.
* Genotype Unknown: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has not undergone predictive testing for HD and therefore has an undetermined carrier status.
* Genotype Negative: This group includes a first or second degree relative (i.e., related by blood to a carrier) who has undergone predictive testing for HD and is known not to carry the HD expansion mutation.
* Family Control: Family members or individuals not related by blood to carriers (e.g., spouses, partners, caregivers).
* Community Controls: Individuals unrelated to HD carriers who did not grow up in a family affected by HD. Data collected from community controls will be used for generation of normative data for sub-studies.
Participant status will be captured in the study database using 2 variables: 1) Investigator Determined Status: this will be based on clinical signs and symptoms and genotyping performed as part of medical care, and will be updated at every visit; and 2) Research Genotyping Status: this will be based on genotyping conducted as part of Enroll-HD study procedures. Based on research genotyping, participants will be reclassified under this variable from Genotype Unknown to 'Carriers' or 'Controls'. Investigators and participants will be blinded to this reclassification.
Exclusion Criteria:
* Individuals who do not meet inclusion criteria,
* Individuals with choreic movement disorders in the context of a negative test for the HD gene mutation.
* For Community Controls: those individuals with a major central nervous system disorder will be excluded (e.g. stroke, Parkinson's disease, multiple sclerosis, etc.).
Participants under 18 may be eligible to participate (if they have juvenile-onset HD).
Primary outcome measure(s)
Motor Assessments: Unified Huntington's Disease Rating Scale (UHDRS) 99 Motor, UHDRS '99 Diagnostic Confidence Level — through study completion, an average of 1 year The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. UHDRS 99 Motor, UHDRS Diagnostic Confidence Level.
Functional Assessments: UHDRS '99 Total Functional Capacity, UHDRS '99 Functional Assessment Scale, UHDRS '99 Independence Scale — through study completion, an average of 1 year The Total Functional Capacity, Functional Assessment and Independence Subscales of the UHDRS '99 will be used to assess participants' functional status. The Total Functional Capacity scale has established psychometric properties including inter-rater reliability and validity, based on radiographic measures of disease progression.
Problem Behaviors Assessment-Short (PBA-s) — through study completion, an average of 1 year The Problem Behavioral Assessment Short Version (PBA-s) will be used to perform behavioral assessments. This instrument measures frequency and severity of symptoms related to altered affect, thought content and coping styles.
Cognitive Assessments: Symbol Digit Modality Test; Stroop Color Naming; Stroop Word Reading; Categorical Verbal Fluency — through study completion, an average of 1 year Cognition will be assessed using the Categorical Verbal Fluency Test, Symbol Digit Modality Test and Stroop Color and Word Reading Test. Verbal fluency is a commonly used neuropsychological test which examines the ability to spontaneously produce words orally within a fixed time span. For category fluency, words must be produced according to semantic constraints. The measure of performance used will be the number of correctly generated words within 60 seconds.
Trial sites (183)
Facility
City
Region
Status
University of Alabama
Birmingham
Alabama
Recruiting
St. Joseph's Hospital and Medical Center
Phoenix
Arizona
Recruiting
University of California - Irvine Medical Center
Irvine
California
Recruiting
Loma Linda Medical Center
Loma Linda
California
Terminated
University of California - Los Angeles
Los Angeles
California
Recruiting
University of California - Davis
Sacramento
California
Recruiting
University of California - San Diego
San Diego
California
Recruiting
University of California - San Francisco
San Francisco
California
Recruiting
Cenexel Rocky Mountain Clinical Research, LLC
Englewood
Colorado
Recruiting
University of Connecticut
Farmington
Connecticut
Recruiting
Georgetown University
Washington D.C.
District of Columbia
Recruiting
University of Florida Board of Trustees
Gainesville
Florida
Recruiting
University of Miami
Miami
Florida
Recruiting
University of South Florida, HDSA Center of Excellence at USF
Tampa
Florida
Recruiting
Emory University, Wesley Woods Health Center
Atlanta
Georgia
Recruiting
Georgia Health Sciences University
Augusta
Georgia
Terminated
Northwestern University
Chicago
Illinois
Recruiting
University of Chicago
Chicago
Illinois
Terminated
Rush University Medical Center
Chicago
Illinois
Recruiting
University of Illinois College of Medicine at Rockford
Rockford
Illinois
Terminated
Indiana University
Indianapolis
Indiana
Recruiting
University of Iowa
Iowa City
Iowa
Recruiting
University of Kansas Medical Center
Kansas City
Kansas
Recruiting
Hereditary Neurological Disease Center
Wichita
Kansas
Recruiting
University of Louisville
Louisville
Kentucky
Recruiting
University of Maryland School of Medicine
Baltimore
Maryland
Withdrawn
Johns Hopkins University
Baltimore
Maryland
Recruiting
Boston University Medical Center
Boston
Massachusetts
Terminated
Beth Israel Deaconess Medical Center
Boston
Massachusetts
Recruiting
University of Michigan
Ann Arbor
Michigan
Recruiting
Wayne State University
Detroit
Michigan
Withdrawn
Hennepin County Medical Center
Minneapolis
Minnesota
Recruiting
Washington University in St. Louis
St Louis
Missouri
Recruiting
University of Nebraska Medical Center
Omaha
Nebraska
Recruiting
Cleveland Clinic - Las Vegas
Las Vegas
Nevada
Recruiting
Cooper University Hospital
Camden
New Jersey
Active Not Recruiting
Rutgers, the State University of New Jersey
New Brunswick
New Jersey
Recruiting
Albany Medical College
Albany
New York
Recruiting
Columbia University
New York
New York
Recruiting
University of Rochester
Rochester
New York
Recruiting
+ 143 more sites — see the full list on the official registry below.
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.